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Abstract. With the increasing use of small animals for human disease studies, small-animal whole-body molecular
imaging plays an important role in biomedical research. Currently, none of the existing imaging modalities
can provide both anatomical and glucose molecular information, leading to higher costs of building dual-modality
systems. Even with image co-registration, the spatial resolution of the molecular imaging modality is not improved.
Utilizing a ring-shaped confocal photoacoustic computed tomography system, we demonstrate, for the first
time, that both anatomy and glucose uptake can be imaged in a single modality. Anatomy was imaged with the
endogenous hemoglobin contrast, and glucose metabolism was imaged with a near-infrared dye-labeled
2-deoxyglucose. © 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.7.076012]
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1 Introduction
The importance of imaging tumor metabolism stems from the
premise that anatomical changes alone are not an accurate
metric for diagnosis, prognosis, and therapy. In particular,
tumor metabolic imaging provides a spatial and temporal
map of therapeutic response and guides treatment planning
and selection. Therefore, simultaneous metabolic and anatomi-
cal imaging is very desirable and necessary not only in clinical
settings but also in preclinical cancer models to improve
our understanding of cancer, metastasis, and drug efficacy
in vivo.1–3
Currently, X-ray computed tomography (CT)4 and magnetic
resonance imaging (MRI)5 provide high-resolution anatomical
images, but they cannot provide sufficient metabolic contrast
without combining with metabolic imaging modalities, such
as positron emission tomography (PET)6 or single-photon emis-
sion computed tomography.7 X-ray CT contrast agents based on
iodine and barium only act as contrast enhancers.4 Magnetic
resonance spectroscopy (MRS) suffers from low sensitivity
and resolution, and requires a high static magnetic field and
a long imaging time (more than 1 h).8 Despite the high cost
of dual-modality imaging systems and the need for image regis-
tration,9 metabolic imaging systems have their own limitations.
Tumor metabolic imaging is based on the principle that cancer
cells uptake more glucose than normal cells due to increased
anaerobic glycolysis (the Warburg effect).10 PET uses 18-F
labeled fluorodeoxyglucose (FDG), a glucose analog, as a radio-
isotope for metabolic imaging.6,11 While PET has high detection
sensitivity, it is expensive; the radioisotopes are difficult to man-
ufacture and have short half-lives.12 In addition, the accumulated
radiation dosage of the combined PET/CT may be carcinogenic
and will confound experimental results in oncology, and thus
cannot be ignored.13–15 Hence, longitudinal monitoring of the
same subject is usually not feasible. Pure optical imaging mod-
alities, such as planar fluorescence imaging (PFI) and fluores-
cence optical tomography (FOT), have also been used to image
tumor glucose metabolism with fluorophores conjugated to
2-deoxyglucose (2DG).16 However, both PFI and FOT suffer
from low spatial resolution and lack of intrinsic contrast, and
have only been used to image tumor metabolism in superficial
tumors.16–19
In this paper, we use a ring-shaped confocal photoacoustic
computed tomography imaging system (RC-PACT)20 to
image both anatomy and tumor glucose metabolism at high spa-
tial resolution in a single imaging modality. The system is based
on the photoacoustic effect, where absorbed laser energy in
tissue generates a local temperature rise, which is subsequently
converted to pressure via thermoelastic expansion.21 RC-PACT
keeps the merits of optical imaging techniques, such as optical
sensitivity and radiation safety, while providing high ultrasound-
defined spatial resolution in optical quasi-diffusive and diffusive
regimes with depth-to-resolution ratios of 100 or greater.21
Additionally, multiple absorbers whose absorption spectra
are different can be spectrally separated by varying the laser
wavelengths.21
In RC-PACT, anatomical images were produced by endogen-
ous hemoglobin contrast, and tumor glucose metabolism was
imaged and quantified by spectrally separating the absorption
of IRDye800-2DG17 from that of hemoglobin. With the unique
design of confocal free-space full-ring light illumination and
full-ring ultrasound transducer array detection, our RC-PACT
system generates in vivo cross-sectional images with simulta-
neous anatomical and metabolic assessments at high spatial
resolution.*These authors contributed equally to this work.
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2 Methods
2.1 RC-PACT Imaging System
The schematic of the RC-PACT system20 is shown in Fig. 1.
A Ti-sapphire laser with the wavelength tunable from 690 to
990 nm was used as the excitation source. The laser beam
passed through a conical lens and an optical condenser to
form a light band around the animal. The maximum light inten-
sity at the light band was approximately 15 mJ∕cm2, which was
below the ANSI limit at the imaging wavelength.22 The photo-
acoustic signals were detected by a 5 cm diameter full-ring
transducer array custom built by Imasonic. The central
frequency of the ultrasound transducer array is 5 MHz, and
the bandwidth is 80% at the −6 dB point.23 Signals from all
512 elements were amplified, selected by 64 8∶1 multiplexers,
and then digitalized by a 64-channel data acquisition system.
The current system can acquire one frame of data per 1.6 s.
2.2 Animal Preparation
The animals were first anesthetized with isoflurane in pure
oxygen using an isoflurane distribution unit (E-Z Anesthesia,
Euthanex) and then mounted to the mouse holder using tape,
with the forelegs attached to the top part of the animal holder
and the hind legs attached to the bottom part. A tube was
attached to the top part of the animal holder to deliver anesthesia
gas. The body of the animal was immersed in a tank of water for
acoustic coupling and surrounded by the full-ring ultrasound
transducer array and sealed at the bottom by a flexible
membrane.
For tumor glucose metabolism imaging experiments with
IRDye800-2DG, the mice were made to fast for 6 hours to max-
imize the uptake of IRDye800-2DG in metabolically active
cells.17
All experimental animal procedures were carried out in con-
formity with the guidelines of the US National Institutes of
Health. The laboratory animal protocols for this work were
approved by the Animal Studies Committee of Washington
University in St. Louis.
2.3 Image Reconstruction
To account for the system’s impulse response, the raw data was
first deconvolved using the Wiener deconvolution. A modified
back-projection algorithm, focal-line reconstruction,24 was used
for the ex vivo kidney imaging. The focal-line reconstruction
algorithm accounts for the elevational focus of the arc-shaped
transducer and renders images with better elevation resolution
and signal-to-noise ratio (SNR).
For the spectral tumor imaging, the iterative half-time recon-
struction algorithm25 was used in order to generate accurate
absorption values. The iterative reconstruction took 20 s per
iteration on a 2.8 GHz processor.
2.4 System Calibration
In the spectral RC-PACT imaging experiments, the beam profile
of the laser varied at different wavelengths, which led to changes
in the fluence distribution, adding complexities on spectral
separation. This problem can be solved either by aligning the
optics after each wavelength tuning, which requires a tremen-
dous amount of time in 3D scanning, or more efficiently, by
compensating post-experiment. We used a phantom calibration
method to compensate for both the laser power and the light
band uniformity of different wavelengths. The phantom was
made from a gelatin-water suspension mixed with 0.1%
black ink. The suspension was filled in a cylindrical container,
with inner diameter similar to the mouse cross-sectional diam-
eter (20 mm), and was then cooled until gelled. The gelled
phantom was then mounted on the RC-PACT imaging system
and imaged using the same scheme as the animal experiment.
Cross-sectional photoacoustic images of the phantom were
reconstructed at each wavelength and the ring-shaped light var-
iation was obtained based on the surface signal of the phantom
image. The matrix of light variation was then used as a weight-
ing function to calibrate the spectral in vivo images.
Fig. 1 Schematic of the full-ring confocal whole-body photoacoustic computed tomography (RC-PACT) system. The dashed box shows a
three-dimensional view of the confocal design.
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2.5 Linear Least Squares Spectral Unmixing Algorithm
The compensated photoacoustic image at each wavelength λi
with spatial coordinates ðx; yÞ in each cross-sectional slice
was assumed to be dependent on the absorption of the endogen-
ous hemoglobin and the exogenous IRDye800-2DG. This can
be written as:
PAðλi; x; yÞ ¼ εHbO2ðλiÞCHbO2ðx; yÞ þ εHbðλiÞCHbðx; yÞ
þ εIRDyeðλiÞCIRDyeðx; yÞ;
where εHbO2ðλiÞ, εHbðλiÞ and εIRDyeðλiÞ are the known molar
absorption coefficients (M−1 cm−1) of oxygenated hemoglobin,
deoxygenated hemoglobin, and IRDye800-2DG at wavelength
λi, respectively. CHbO2ðx; yÞ, CHbðx; yÞ, and CIRDyeðx; yÞ are the
molar (M) concentrations of oxygenated hemoglobin, deoxyge-
nated hemoglobin, and IRDye800-2DG at location ðx; yÞ,
respectively.
The relative concentrations of the three dominant absorbers
were estimated by solving the set of linear equations using the
linear least squares model with a constraint that the concentra-
tions of any absorbers cannot be negative. Negative concentra-
tions were set to zero.
2
4
CHbO2ðx; yÞ
CHbðx; yÞ
CIRDyeðx; yÞ
3
5 ¼ ðεTεÞ−1εTG;
where,
G ¼
2
64
PAðλ1; x; yÞ
PAðλ2; x; yÞ
PAðλ3; x; yÞ
3
75 and
ε ¼
2
64
εHbO2ðλ1Þ εHbðλ1Þ εIRDyeðλ1Þ
εHbO2ðλ2Þ εHbðλ2Þ εIRDyeðλ2Þ
εHbO2ðλ3Þ εHbðλ3Þ εIRDyeðλ3Þ
3
75:
The calculated concentrations have arbitrary units. Their
ratios, however, are meaningful and can be used to estimate
absolute concentrations. The total hemoglobin concentration
(HbT) at each pixel is estimated by the following relationship:
HbTðx; yÞ ¼ CHbO2ðx; yÞ þ CHbðx; yÞ:
Then the ratio of relative HbTðx; yÞ to IRDye800-2DG con-
centrations at each pixel was used to estimate the absolute
concentrations of IRDye800-2DG in vivo for A431 and
786-O tumor mice images.
2.6 Phantom Experiment for Absolute
Concentration Estimation
IRDye800-2DG (Licor Biosciences, USA) stock solution was
prepared by dissolving 100 nanomoles in 1 mL sterile PBS buf-
fer at pH 7.4. The stock solution was then diluted to IRDye800-
2DG solutions at four different concentrations—16.7, 4.18,
1.11, and 0.55 μM, respectively. Each of these solutions and
oxygenated bovine blood were loaded in five Silastic® tubes
(Dow Corning, USA; inner diameter 0.3 mm; outer diameter
0.64 mm). These tubes were then glued to a 2 cm diameter gela-
tin cylinder.
3 Results
3.1 Ex vivo Absolute Concentration Estimation
The phantom was scanned by the RC-PACT imaging system at
three wavelengths—776, 796, and 820 nm—to capture the
absorption profile of IRDye800-2DG solution [(Fig. 2(a)].
The SNR of the signals from each of the tubes was calculated
for the image acquired at 776 nm [Fig. 2(b)], by computing the
Fig. 2 (a) Molar absorption spectra of the two forms of hemoglobin and
IRDye800-2DG. (b) SNR of RC-PACT signals from tubes containing
IRDye800-2DG with different concentrations. (c) IRDye800-2DG con-
centrations in tubes estimated using the linear least squares spectral
unmixing algorithm versus the actual concentrations.
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ratio of the photoacoustic signals in the tube to the standard
deviation of the background (the regions between the tubes).
The three RC-PACT images were reconstructed using the
focal-line reconstruction algorithm,24 and then compensated
for wavelength-dependent laser power variation using the
RC-PACT images of the ink phantom. Then these images
were processed using a linear least squares spectral unmixing
algorithm26 to determine the relative concentrations of HbT
and IRDye800-2DG in the five tubes. The HbT relative concen-
tration image was scaled to 2.3 mM, and then the absolute con-
centration of each of the four IRDye800-2DG solutions was
estimated. The predicted concentrations were averaged along
each respective tube, and the mean and standard deviations cal-
culated. Figure 2(c) shows the mean and standard deviation for
each of the estimated IRDye800-2DG concentrations.
3.2 Tumor Glucose Metabolism Imaging
Using RC-PACT
To investigate the in vivo capability of our system to simulta-
neously image anatomy and tumor metabolism, we imaged
an athymic mouse bearing a subcutaneous xenografted A431
tumor. In vivo control RC-PACT images were acquired over
an elevational distance of 10 mm with a 0.2-mm step size.
At each elevational step, photoacoustic signals from all 512
transducers were acquired at three wavelengths—776, 796,
and 820 nm. This served as a control experiment, since the
dye was not injected.
Twenty-four hours after intravenous tail vein administration
of 200 μL (0.4 mM) IRDye800-2DG solution, multispectral
RC-PACT images were acquired using the same procedure as
the control experiment. Tomographic inversion was performed
to render images with a 0.05 × 0.05 mm2 pixel size. The recon-
structed images were then compensated for by RC-PACT
images of a phantom for wavelength-dependent laser power
and beam shape variations in the illumination ring.
Figure 3(a) shows a representative anatomical cross-section
of the A431 tumor-bearing mouse acquired at 776 nm. Then the
linear least squares unmixing algorithm was applied on every
pixel of spectral RC-PACT images to calculate the relative
HbT and IRDye800-2DG. The relative HbT concentrations
were normalized by the maximum HbT concentration (observed
in vena cava) and then scaled to 2.3 mM to recover the absolute
concentration [Fig. 3(b)]. The absolute concentration of
IRDye800-2DG at each pixel was then estimated by using
the HbT concentration as a reference. After the experiment,
the A431 tumor-bearing mouse was imaged using a lab-made
fluorescence imager.
Figure 3(c) is an image of tumor glucose metabolism
(IRDye800-2DG concentration map) overlaid on the gray-scale
RC-PACT image acquired at 776 nm. The IRDye800-2DG con-
centration in the healthy skin area marked “HS” was used as the
threshold for the image in Fig. 3(c). The uptake of IRDye800-
2DG in the liver was nonuniform and twice as high as in the
normal tissue, which agrees with the elevated expression of
GLUT1 transporters in liver tissue.17 The role of GLUT1 trans-
porters in uptaking IRDye800-2DG has been investigated by
competitive binding assays and dose-dependence experiments
in a variety of tumor cell lines.17 Despite the reported role
of GLUT1 transporters,17 the exact uptake mechanism of
IRDye800-2DG may be different from that of FDG or native
glucose due to differences in molecular size.
Elevated uptake of IRDye800-2DG at the outer tumor sur-
face and inner skin-tumor interface was three times higher
than that in the normal tissue in Fig. 3(c), indicating hypermeta-
bolic (HM) activity. The RC-PACT imaging data also agreed
with the fluorescence imaging results [Fig. 3(d)], which indi-
cated a tumor-to-normal tissue contrast of approximately 3.
The same image reconstruction and spectral separation methods
were also applied on the control RC-PACT images, and no
significant IRDye800-2DG uptake was observed.
As shown in Fig. 3(c), there is some uptake of IRDye800-
2DG inside the tumor, but higher uptake is reflected at the tumor
interfaces than in the tumor core. At least two explanations are
possible (i) Based on the histology image in Fig. 3(e), the den-
sity of tumor cells in the tumor core is not very high. The com-
paratively lower uptake in this area may reflect the lower cell
density. (ii) Figure 3(e) shows migrating tumor cells gathered
at the muscle/tissue interface [inner interface in Fig. 3(c)].
These particularly active cells may have higher metabolic
demand than cells in the core of the tumor. Therefore, the uptake
may be higher at the interfacial boundaries.
Fig. 3 In vivo images of an A431 tumor xenografted in the mouse skin.
RC-PACT images of (a) the anatomy acquired at 776 nm (red boun-
dary indicates the liver region), (b) HbT concentration (HbT), and
(c) IRDye800-2DG concentration (DG) overlaid on the anatomical
image. (d) In vivo fluorescence image of the cancerous skin, showing
the IRDye800-2DG distribution. HS, the healthy skin; HM, hypermeta-
bolic, (e) Hematoxylin and eosin stained histology image of the excised
A431 tumor (Magnification: 4X). Magnified view showing A 431 tumor
cells migrating into the muscle tissue interface (Magnification: 20X)
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To showcase the capability of our RC-PACT system to image
the glucose metabolism of deeper tumors, we imaged two mice
with orthotopically implanted 786-O tumor cells in their left
kidneys. Following the control experiment, 200 μL of
(0.4 mM) IRDye800-2DG was administered, and the mice were
imaged after 24 h. This 24-h time window is sufficient for excess
unbound IRDye800-2DG to be excreted by the kidneys and
bladder. This also increases the likelihood that the imaged
IRDye800-2DG reflects tumor glucose metabolism rather
than the physical entrapment of excess IRDye800-2DG mole-
cules within the tumor. After the in vivo experiment,
the mice were sacrificed and the kidneys were excised for
ex vivo RC-PACT imaging.
Figure 4(a) shows representative anatomical cross-
sections of the two 786-O tumor-bearing mice. The linear
least squares spectral unmixing algorithm was applied on the
Fig. 4 In vivo RC-PACT images of orthotopically implanted 786-O kidney tumors. Top row: mouse 1. Bottom row: mouse 2. (a) Anatomical images
acquired at 776 nm. (b) HbT concentration (HbT) images overlaid on the anatomical images. (c) IRDye800-2DG concentration (DG) images overlaid
on the anatomical images. CK, cancerous kidney; HK, healthy kidney; HM, hypermetabolic.
Fig. 5 Ex vivo RC-PACT images of freshly excised healthy and tumor bearing kidneys. Top row: mouse 1. Bottom row: mouse 2. (a) Maximum-
amplitude-projection RC-PACT anatomical images acquired at 776 nm. (b) HbT concentration (HbT) images overlaid on the anatomical images
acquired at the same cross-section. (c) IRDye800-2DG concentration [DG] images overlaid on the anatomical images acquired at the same
cross-section. CK, cancerous kidney; HK, healthy kidney; HM, hypermetabolic.
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multi-wavelength RC-PACT images, and relative concentrations
of HbT and IRDye800-2DG were calculated. The HbT concen-
trations were normalized by the maximum HbT concentration
(observed in vena cava), scaled to 2.3 mM [Fig. 4(b)], and
then the absolute IRDye800-2DG concentrations in the anato-
mical cross-section were estimated.
Images of tumor glucose metabolism [Fig. 4(c)] were over-
laid on the gray-scale PACT images acquired at 776 nm. In
Fig. 4(c), the mean IRDye800-2DG concentration in healthy
kidneys was used as the threshold to account for non-specific
IRDye800-2DG uptake due to kidneys being the excretory
route. The SNR for imaging IRDye800-2DG in the most meta-
bolically active site in the tumor was 39.3 dB for mouse 1 and
38.3 dB for mouse 2. The tumor-to-normal tissue contrast for
IRDye800-2DG uptake was approximately 3.3 at the most meta-
bolically active site in the tumor. The same image reconstruction
and spectral separation methods were also applied on the control
RC-PACT images and no significant IRDye800-2DG uptake
was observed.
3.3 Ex vivo RC-PACT Imaging of Excised Kidneys
Ex vivo experiments were performed using the top illumination
scheme of RC-PACT The freshly excised kidneys were sealed in
a gelatin phantom and scanned in the elevation direction. Multi-
wavelength ex vivo RC-PACT images were reconstructed using
the focal-line reconstruction algorithm.24 The relative concentra-
tions of HbT and IRDye800-2DG were determined by the linear
least squares algorithm for every pixel. Figure 5(a) shows max-
imum-amplitude-projected images. Images of HbT [Fig. 5(b)]
and IRDye800-2DG dye concentrations [Fig. 5(c)] are superim-
posed on the anatomical image acquired at 776 nm.
Figure 5 shows that endogenous hemoglobin contrast is pre-
sent in both normal and tumor-bearing kidneys at similar con-
centrations. However, the tumor-bearing kidneys of both mice
displayed higher IRDye800-2DG uptake than their normal
counterparts. This uptake is not uniform in the tumors, possibly
due to the differences in metabolic demand within the tumor
mass. Additionally, necrotic tissue within the tumor may not
uptake IRDye800-2DG. The average tumor-to-normal tissue
contrast for excised kidneys of both mice was approximately 3.
4 Discussion
Molecular and anatomical imaging is of great importance due
to its wide application in tumor biology, drug discovery, and
early-stage cancer screening in both clinical and pre-clinical
settings. In this report, we have demonstrated that RC-PACT
provided tumor glucose metabolism and anatomic images with
ultrasound-defined spatial resolution in a single imaging mod-
ality. While PET-CT and PET-MRI have been well established
in the field,3 RC-PACT is a promising and less expensive
alternative with the advantages of non-ionizing laser radiation,
non-radioactive optical contrast, and endogenous hemoglobin
contrast. Additionally, image co-registration of anatomical and
metabolic assessments is automatic.
Combined with spectral imaging,27 RC-PACT also offers
the possibility of resolving exogenous contrast agents, such as
IRDye800-2DG. In tumor glucose metabolism imaging experi-
ments, the wavelengths were selected to capture the steep
changes in the absorption spectrum of IRDye800-2DG within
a narrow spectral band of 40 nm. In this spectral region, the
light scattering properties of the tissue are not expected to differ
by more than 10% to 12%. Since the image contrast in
photoacoustics is proportional to the product of absorption coef-
ficient and local fluence, simple linear least squares spectral
unmixing of multi-wavelength photoacoustic images may not
be accurate in general. However, exceptions can be made
when the chromophore to be resolved is surrounded by chromo-
phores with relatively constant spectrum and/or are relatively
weakly absorbing.28 In our spectral range, the absorption of
IRDye800-2DG declines rapidly as the wavelength increases,
while the absorptions of oxy- and deoxy-hemoglobin are rela-
tively unchanging. This absorption characteristic makes the lin-
ear least squares technique to be reasonable for resolving the
IRDye800-2DG from background tissue hemoglobin absorp-
tion.28 We tested the validity of our method of determining
the absolute concentration of IRDye800-2DG using HbT by
performing phantom experiments.
Besides imaging tumor glucose metabolism, RC-PACT can
also benefit from near- infrared fluorescent dyes29,30 for deep
molecular imaging along with detailed, high resolution anatomi-
cal imaging. The possibility of multiplexing molecular imaging
with anatomical imaging uniquely positions RC-PACT to have
a broad impact in preclinical medical research and life sciences.
In addition, as photoacoustic tomography has been extended to
imaging biological tissue as deeply as 5 cm, RC-PACT holds the
promise for molecular clinical imaging by scaling up the system
for humans.
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